2. Search Result
Search Result
Results for "

Streptozotocin

" in MedChemExpress (MCE) Product Catalog:

37

Inhibitors & Agonists

3

Biochemical Assay Reagents

1

Peptides

4

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13753
    Streptozotocin
    Maximum Cited Publications
    51 Publications Verification

    Streptozocin; NSC-85998; U 9889

    		 DNA/RNA Synthesis DNA Alkylator/Crosslinker Autophagy Bacterial Antibiotic Apoptosis Infection Cancer
    Streptozotocin (Streptozocin; STZ) is an antibiotic widely used in experimental animal models of induced diabetes. Streptozotocin enters B cells via the glucose transporter (GLUT2) and causes the alkylation of DNA ( DNA-methylating ). Streptozotocin can induce the apoptosis of β cells .
    Streptozotocin
  • HY-103290
    R715

    		Bradykinin Receptor Others
    R715 is a selective bradykinin B1 receptor antagonist. R715 significantly attenuates the hyperalgesic effect developed in Streptozotocin(HY-13753)-diabetic mice .
    R715
  • HY-N3015
    Bruceine E

    		Others Metabolic Disease
    Bruceine E is a quassinoid from seeds of Brucea javanica (L.) Merr, exhibiting hypoglycemia effect . Bruceine E exhibits blood glucose lowering effect in both nondiabetic mice and Streptozotocin (STZ (HY-13753))-induced diabetic rats at lower dose .
    Bruceine E
  • HY-Y1841
    o-Phenanthroline monohydrate
    3 Publications Verification

    1,10-Phenanthroline monohydrate

    		 MMP Others
    o-Phenanthroline (1,10-Phenanthroline) monohydrate, a metal chelator, prevents the induction of chromosomal aberrations in streptozotocin-treated cells. o-Phenanthroline monohydrate forms a red chelate with Fe 2+ that absorbs maximally at 510 nm. o-Phenanthroline (1,10-Phenanthroline) monohydrate is also a MMP inhibitor .
    o-Phenanthroline monohydrate
  • HY-103567
    Desmethyl-YM-298198 hydrochloride

    		mGluR Neurological Disease
    Desmethyl-YM-298198 hydrochloride is a high-affinity, selective, and noncompetitive mGluR1 antagonist (IC50: 16 nM). Desmethyl-YM-298198 hydrochloride has analgesic effect in Streptozotocin (HY-13753)-induced hyperalgesic mice .
    Desmethyl-YM-298198 hydrochloride
  • HY-103567A
    Desmethyl-YM-298198

    		mGluR Neurological Disease
    Desmethyl-YM-298198 is a high-affinity, selective, and noncompetitive mGluR1 antagonist (IC50: 16 nM). Desmethyl-YM-298198 has analgesic effect in Streptozotocin (HY-13753)-induced hyperalgesic mice .
    Desmethyl-YM-298198
  • HY-151138
    α-Glucosidase-IN-16

    		Glucosidase Metabolic Disease
    α-Glucosidase-IN-16 is a potent and orally active α-glucosidase inhibitor with an IC50 value of 3.28 μM. α-Glucosidase-IN-16 can reduce the level of blood glucose in Streptozotocin-induced diabetic rats. Antidiabetic activity .
    α-Glucosidase-IN-16
  • HY-160186
    20-SOLA

    		Others Cardiovascular Disease
    20-SOLA is the first water soluble and orally active 20-HETE antagonist. 20-SOLA greatly ameliorates changes in blood pressure and renal injury associated with a streptozotocin (STZ (HY-13753))-diabetic mouse model. 20-SOLA also is a GPR75 receptor blocker. 20-SOLA can be used for the research of cardiovascular pathologies .
    20-SOLA
  • HY-111327
    Valibose

    		Glucosidase Metabolic Disease
    Valibose is analpha-glucosidaseinhibitor, and ameliorates the metabolic disorder of glucose and lipids and the nephropathy in Streptozotocin (HY-13753)-induced diabetic rats .
    Valibose
  • HY-131542
    APPA

    		Aldose Reductase Apoptosis Metabolic Disease
    APPA is an aldose reductase inhibitor. APPA can effectively prevent apoptosis and the symptoms of Streptozotocin (HY-13753)-induced diabetes by inhibiting the polyol pathway in rats. APPA has the potential for diabetic nephropathy (DN) research .
    APPA
  • HY-169117
    α-Glucosidase-IN-74

    		Glucosidase Metabolic Disease
    α-Glucosidase-IN-74 (Compound 7d), an isatin-thiazole derivative, is a α-glucosidase inhibitor. α-Glucosidase-IN-74 exhibits antidiabetic activity by decreasing glycaemia and triglyceride levels in Streptozotocin (HY-13753)-induced diabetic animals .
    α-Glucosidase-IN-74
  • HY-124244
    DB-959

    PPARδ/γ agonist 1

    		 PPAR Neurological Disease
    DB-959 (PPARδ/γ agonist 1) is a potent PPAR agonist targeting PPARδ/γ. DB-959 improves spatial learning and memory in mice induced by Streptozotocin (HY-13753) and has the potential to improve Alzheimer's disease (AD). .
    DB-959
  • HY-W004544
    o-Phenanthroline
    3 Publications Verification

    1,10-Phenanthroline

    		 MMP Others
    o-Phenanthroline (1,10-Phenanthroline), a metal chelator, prevents the induction of chromosomal aberrations in streptozotocin-treated cells. o-Phenanthroline (1,10-Phenanthroline) forms a red chelate with Fe 2+ that absorbs maximally at 510 nm. o-Phenanthroline (1,10-Phenanthroline) is also a MMP inhibitor .
    o-Phenanthroline
  • HY-122075
    FR 78844

    		Others Metabolic Disease
    FR 78844 is a potent and orally active bone resorption inhibitor. FR 78844 has the potential for the research of diabetes associated osteopenia .
    FR 78844
  • HY-N12353
    Stevisalioside A

    		Phosphatase Metabolic Disease
    Stevisalioside A (Compound 2) can be isolated from Stevia serrata roots. Stevisalioside A is an orally active antidiabetic agent. Stevisaliosides A inhibits PTP1B (IC50: 526.8 μM). Stevisalioside A reduces blood glucose levels and the postprandial peak in oral glucose and insulin tolerance tests in Streptozotocin (HY-13753) induced hyperglycemic mice .
    Stevisalioside A
  • HY-163853
    Antidiabetic agent 6

    		GLUT Akt Metabolic Disease
    Antidiabetic agent 6 (Compound 19) is an antidiabetic Agent. Antidiabetic agent 6 stimulates GLUT4 translocation by activation of the PI3K/AKT-dependent signaling pathway. Antidiabetic agent 6 reduces blood glucose levels in Streptozotocin (HY-13753)-induced diabetic rats .
    Antidiabetic agent 6
  • HY-19415A
    SB-435495 hydrochloride

    		Phospholipase Metabolic Disease
    SB-435495 hydrochloride is a potent, selective, reversible, non-covalent and orally active Lp-PLA2 inhibitor with an IC50 of 0.06 nM .
    SB-435495 hydrochloride
  • HY-19415B
    SB-435495 ditartrate

    		Phospholipase Metabolic Disease
    SB-435495 ditartrate is a potent, selective, reversible, non-covalent and orally active Lp-PLA2 inhibitor with an IC50 of 0.06 nM .
    SB-435495 ditartrate
  • HY-W004544S
    o-Phenanthroline-d8

    1,10-Phenanthroline-d8

    		 Isotope-Labeled Compounds MMP Others
    o-Phenanthroline-d8 is the deuterium labeled o-Phenanthroline. o-Phenanthroline (1,10-Phenanthroline), a metal chelator, prevents the induction of chromosomal aberrations in streptozotocin-treated cells. o-Phenanthroline (1,10-Phenanthroline) forms a red chelate with Fe2+ that absorbs maximally at 510 nm. o-Phenanthroline (1,10-Phenanthroline) is also a MMP inhibitor[1][2].
    o-Phenanthroline-d8
  • HY-13999A1
    NSI-189 phosphate

    		Others Neurological Disease
    NSI-189 phosphate is the phosphate salt form of NSI-189 (HY-13999). NSI-189 phosphate stimulates the neurogenesis of neural stem cells. NSI-189 phosphate exhibits neuroprotective effect in Streptozotocin (HY-13753)-induced diabetic mouse model, improves neurological function and cognitive ability after stroke in rat middle cerebral artery occlusion (MCAo) model, and exhibits antidepressant efficacy .
    NSI-189 phosphate
  • HY-Q40876
    BBT

    		Calcium Channel Metabolic Disease
    BBT is an enhancer of impaired glucose-stimulated insulin secretion (GSIS). BBT exhibits anti-hyperglycemia activity, and protects β-cells from cytokine- or streptozotocin (STZ (HY-13753))-induced cell death in type 2 diabetes models. BBT acts function via cAMP/PKA and long-lasting (L-type) voltage-dependent Ca2+ channel/CaMK2 pathway .
    BBT
  • HY-17451
    Glibornuride

    		Potassium Channel Metabolic Disease
    Glibornuride is a blocker of ATP-sensitive K + channels (KATP channel) with a pKi of 5.75 . Antidiabetic agent .
    Glibornuride
  • HY-17451R
    Glibornuride (Standard)

    		Potassium Channel Metabolic Disease
    Glibornuride (Standard) is the analytical standard of Glibornuride. This product is intended for research and analytical applications. Glibornuride is a blocker of ATP-sensitive K+ channels (KATP channel) with a pKi of 5.75 . Antidiabetic agent .
    Glibornuride (Standard)
  • HY-163005
    α-Glucosidase-IN-43

    		Glucosidase Metabolic Disease
    α-Glucosidase-IN-43 (compound AS14) is an α-glucosidase inhibitor (IC50: 4.32 μM) with acute hypoglycemic activity. α-Glucosidase-IN-43 exhibits safety and in vivo efficacy, is nontoxic to normal mouse fibroblasts, and is able to rescue streptozotocin (HY-13753)-induced diabetic rats. α-Glucosidase-IN-43 can be used to study postprandial hyperglycemia in diabetic patients .
    α-Glucosidase-IN-43
  • HY-18555
    TMPA
    2 Publications Verification

    		 Nuclear Hormone Receptor 4A/NR4A AMPK Metabolic Disease Inflammation/Immunology Cancer
    TMPA is a high-affinity Nur77 antagonist that binds to Nur77 leading to the release and shuttling of LKB1 in the cytoplasm to activate AMPKα. TMPA effectively lowers blood glucose and attenuates insulin resistance in type II db/db, high-fat diet and streptozotocin-induced diabetic mice. TMPA reduces RICD (restimulation-induced cell death) in human T cells, can also be used in studies of cancer and T-cell apoptosis dysregulation .
    TMPA
  • HY-162639
    α-Glucosidase-IN-68

    		Glucosidase Cholinesterase (ChE) Neurological Disease Metabolic Disease
    α-Glucosidase-IN-68 (Compound 2) is an inhibitor for α-Glucosidase, AChE, and BChE, with IC50 of 0.251, 0.774 and 0.793 μM, respectively. α-Glucosidase-IN-68 exhibits antioxidant efficacy, with IC50 of 0.69 μM and 0.02 μM, in DPPH and ABTS experiments. α-Glucosidase-IN-68 exhibits antidiabetic effect in Streptozotocin (HY-13753)-induced diabetic rat models .
    α-Glucosidase-IN-68
  • HY-164595
    IHMT-MST1-39

    		Hippo (MST) Apoptosis AMPK Metabolic Disease
    IHMT-MST1-39 is an orally active inhibitor for MST kinase, with IC50 of 42 nM and 109 nM, for MST1 and MST2. IHMT-MST1-39 activates the AMPK signaling pathway in liver cells, reduces apoptosis of pancreatic β-cells. IHMT-MST1-39 ameliorates diabetes in Streptozotocin (HY-13753)-induced type 1 diabetes (T1D) mouse models .
    IHMT-MST1-39
  • HY-107510
    YM-230888

    		mGluR Neurological Disease
    YM-230888 is an orally active, selective and allosteric mGlu1 receptor antagonist with a Ki of 13 nM. YM-230888 inhibits mGlu1-mediated inositol phosphate production in rat cerebellar granule cells with an IC50 of 13 nM. YM-230888 shows antinociceptive response in Streptozotocin (HY-13753)-induced hyperalgesia models. YM-230888 significantly reduces pain parameters in complete Freund's adjuvant (HY-153808)-induced arthritic pain models .
    YM-230888
  • HY-145549
    C20 Sphingomyelin (d18:1/20:0)

    N-eicosanoyl-D-erythro-Sphingosylphosphorylcholine; SM(d18:1/20:0)

    		 Others Infection
    C20 Sphingomyelin is a naturally occurring sphingolipid. Levels of C20 sphingomyelin are upregulated in the hippocampus of rats with diabetes induced by streptozotocin (HY-13753) and in human plasma where it is positively correlated with insulin resistance in obese humans. C20 sphingomyelin is also upregulated in the liver of a mouse model of Niemann-Pick type C1 disease, a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder. The plasma concentration of C20 sphingomyelin is decreased in men with prostate cancer. As this product is derived from a natural source, there may be variations in the sphingoid backbone.
    C20 Sphingomyelin (d18:1/20:0)
  • HY-162681
    eeAChE-IN-3

    		Cholinesterase (ChE) Interleukin Related Neurological Disease
    eeAChE-IN-3 (compound YS3g) is an orally active, potent EeAChE and IL-6 inhibitor with IC50s of 0.54 μM, 0.49 μM, 8.54 μM and 0.57 μM for EeAChE, RatAChE, RatBuChE and IL-6, respectively. eeAChE-IN-3 improves STZ (HY-13753) (Streptozotocin; HY-13753)-induced learning and memory impairment in mice. eeAChE-IN-3 has the potential for Alzheimer's disease (AD) research .
    eeAChE-IN-3
  • HY-168214
    Kv7.2/Kv7.3 agonist 1

    		Potassium Channel Neurological Disease
    Kv7.2/Kv7.3 agonist 1 (Compound 16) is an orally active agonist for KV7.2/7.3 channel (KCNQ2/3) with an EC50 of 1.03 μM. Kv7.2/Kv7.3 agonist 1 exhibits analgesic efficacy in mice chronic constriction injury (CCI) model and mice Streptozotocin (HY-13753)-induced diabetic peripheral neuropathic pain (DPNP) model, with ED50 of 12.02 and 9.63 mg/kg .
    Kv7.2/Kv7.3 agonist 1
  • HY-116005
    A-286501

    		Adenosine Kinase Neurological Disease Inflammation/Immunology
    A-286501 is an orally active and potent carbocyclic nucleoside adenosine kinase inhibitor with an IC50 value of 0.47 nM, which shows analgesic and anti-inflammatory effects. A-286501 reduces nociception in animal models of acute (thermal), inflammatory (formalin and carrageenan) and neuropathic (L5/L6 nerve ligation and streptozotocin-induced diabetic) pain. A-286501 also reduces Carrageenan (HY-125474)-induced paw edema and myeloperoxidase activity in the injured paw. A-286501 is promising for research of analgesic and anti-inflammatory agents .
    A-286501
  • HY-161682
    GPR84 antagonist 9

    		GPR84 Neurological Disease
    GPR84 antagonist 9 (compound 320) is an orally active GPR84 antagonist with the IC50 of 0.012 μM. GPR84 antagonist 9 can be used for study of inflammatory-driven pain diseases .
    GPR84 antagonist 9
  • HY-10863
    Anandamide
    1 Publications Verification

    AEA

    		 Cannabinoid Receptor PPAR TRP Channel GPR55 Fungal Tau Protein Endogenous Metabolite Infection Neurological Disease Metabolic Disease Inflammation/Immunology
    Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis .
    Anandamide
  • HY-W127391
    1,2-Dilaurin

    (Rac)-1,2-Didodecanoylglycerol

    		 Biochemical Assay Reagents Others
    1,2-Dilaurin is a diacylglycerol containing lauric acid at the sn-1 and sn-2 positions. It has been used as an internal standard for the quantification of diglycerides in rat desheathed sciatic nerves. [1] Monomolecular films containing 1,2-dilauroyl-rac-glycerol have been used as substrates to measure surface pressure and the effect of pancreatic procolipase and colipase on porcine pancreatic lipase activity. [2] References: [1]. Zhu, X. and Eichberg, J. 1,2-Diacylglycerol content and its arachidonyl-containing molecular species are reduced in the sciatic nerve of streptozotocin-induced diabetic rats. J. Neurochemistry. 55(3), 1087-1090 (1990).[2]. Wieloch, T., Borgstr m, B., Piéroni, G. et al. Porcine trypsinogen and its trypsin-activated form: lipid binding and lipase activation on monomolecular membranes. FEBS Express. 128(2), 217-220 (1981).
    1,2-Dilaurin
  • HY-117626
    LP-935509

    		AAK1 Cyclin G-associated Kinase (GAK) SARS-CoV Infection Neurological Disease Inflammation/Immunology
    LP-935509 is an orally active, potent, selective, ATP-competitive and brain-penetrant inhibitor of adaptor protein-2 associated kinase 1 (AAK1) with an IC50 of 3.3 nM and a Ki of 0.9 nM, respectively. LP-935509 is also a potent inhibitor of BIKE (IC50=14 nM) and a modest inhibitor of GAK (IC50=320 nM). LP-935509 shows antinociceptive activity. LP-935509 can be used for neuropathic pain and SARS-CoV-2 research .
    LP-935509
  • HY-106024A
    Alagebrium bromide

    ALT711 bromide

    		 Others Infection
    Alagebrium bromide is a cross-link breaker. This study investigated the role of advanced glycation end products (AGEs) in mediating protein kinase C (PKC) isoform expression in diabetic nephropathy. In vitro, vascular smooth muscle cells cultured in high glucose (25-mmol/l) showed increased translocation and expression of PKC-α compared with cells cultured in low glucose (5-mmol/l). Coculture with ALT-711 more effectively attenuated the increased expression and translocation of PKC-α compared with aminoguanidine, an inhibitor of AGE formation. Streptozotocin-induced diabetic rats were randomized to no treatment, ALT-711 treatment, or aminoguanidine treatment. Diabetes induced an increase in PKC-α as well as -βI, -βII, and -ε isoforms. ALT-711 and aminoguanidine treatment, both of which attenuated renal AGE accumulation, abolished these increases in PKC expression. However, only ALT-711 reduced the translocation of phosphorylated PKC-α from the cytoplasm to the membrane. ALT-711 treatment attenuated the expression of vascular endothelial growth factor (VEGF) and extracellular matrix proteins (fibronectin and laminin) and was associated with a reduction in albuminuria. Aminoguanidine had no effect on VEGF expression, although a reduction in fibronectin and laminin was observed. These findings suggest that AGEs are important stimulators of PKC activation, particularly PKC-α, in patients with diabetic nephropathy, which can be directly inhibited by ALT-711.
    Alagebrium bromide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: